FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.

"Competing interests WEF and JLM are employees of GlycoMimetics. AL is an employee of Daiichi Sankyo, Inc. The other authors declare no competing interests."

"This study was supported in part by the National Institutes of Health through The University of Texas Anderson’s Cancer Center Support Grant (P30 CA016672), The University of Texas MD Anderson Cancer Moon Shots Program (MDS/AML program), and the Paul & Mary Haas Endowment (Chair in Genetics). Research funding support was also received from GlycoMimetics, Daiichi Sankyo, and the Chinese Academy of Medical Sciences & Peking Union Medical College’s Institute of Hematology & Hospital of Blood Diseases. The authors would like to thank Editing Services, Research Medical Library, The University of Texas M.D. Anderson Cancer Center for providing critical reviews and editorial assistance in the preparation of this manuscript."